Compare STRIDES PHARMA SCIENCE with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs SANOFI INDIA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE SANOFI INDIA STRIDES PHARMA SCIENCE/
SANOFI INDIA
 
P/E (TTM) x 7.7 40.9 18.8% View Chart
P/BV x 0.9 7.2 12.9% View Chart
Dividend Yield % 0.5 1.2 43.3%  

Financials

 STRIDES PHARMA SCIENCE   SANOFI INDIA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA
Dec-18
STRIDES PHARMA SCIENCE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,1476,840 16.8%   
Low Rs6424,630 13.9%   
Sales per share (Unadj.) Rs317.21,203.1 26.4%  
Earnings per share (Unadj.) Rs7.8165.3 4.7%  
Cash flow per share (Unadj.) Rs25.1209.9 11.9%  
Dividends per share (Unadj.) Rs2.0084.00 2.4%  
Dividend yield (eoy) %0.21.5 15.3%  
Book value per share (Unadj.) Rs274.3963.6 28.5%  
Shares outstanding (eoy) m89.5023.03 388.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.8 59.1%   
Avg P/E ratio x114.034.7 328.6%  
P/CF ratio (eoy) x35.727.3 130.6%  
Price / Book Value ratio x3.36.0 54.8%  
Dividend payout %25.550.8 50.2%   
Avg Mkt Cap Rs m80,058132,078 60.6%   
No. of employees `0002.53.3 75.9%   
Total wages/salary Rs m4,3414,068 106.7%   
Avg. sales/employee Rs Th11,325.88,393.8 134.9%   
Avg. wages/employee Rs Th1,731.41,232.4 140.5%   
Avg. net profit/employee Rs Th280.11,153.0 24.3%   
INCOME DATA
Net Sales Rs m28,39427,708 102.5%  
Other income Rs m941897 104.9%   
Total revenues Rs m29,33428,605 102.5%   
Gross profit Rs m3,9656,235 63.6%  
Depreciation Rs m1,5401,027 150.0%   
Interest Rs m1,9627 28,034.3%   
Profit before tax Rs m1,4036,098 23.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,292 4.2%   
Profit after tax Rs m7023,806 18.4%  
Gross profit margin %14.022.5 62.1%  
Effective tax rate %6.937.6 18.4%   
Net profit margin %2.513.7 18.0%  
BALANCE SHEET DATA
Current assets Rs m24,83615,922 156.0%   
Current liabilities Rs m18,9936,235 304.6%   
Net working cap to sales %20.635.0 58.9%  
Current ratio x1.32.6 51.2%  
Inventory Days Days7164 111.5%  
Debtors Days Days11321 543.5%  
Net fixed assets Rs m34,2897,539 454.8%   
Share capital Rs m895230 389.1%   
"Free" reserves Rs m23,65121,962 107.7%   
Net worth Rs m24,54622,192 110.6%   
Long term debt Rs m15,5130-   
Total assets Rs m65,43729,839 219.3%  
Interest coverage x1.7872.1 0.2%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.9 46.7%   
Return on assets %4.112.8 31.9%  
Return on equity %2.917.2 16.7%  
Return on capital %6.927.5 25.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6977,587 206.9%   
Fx outflow Rs m7357,145 10.3%   
Net fx Rs m14,962442 3,385.0%   
CASH FLOW
From Operations Rs m1,8713,739 50.0%  
From Investments Rs m5,826-731 -797.0%  
From Financial Activity Rs m-10,157-1,972 515.1%  
Net Cashflow Rs m-2,6151,036 -252.4%  

Share Holding

Indian Promoters % 27.7 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 37.8 14.4 262.5%  
FIIs % 8.6 14.6 58.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 15,184 370.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   UNICHEM LAB  VENUS REMEDIES  STERLING BIOTECH  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Up; Telecom Stocks Rally(09:30 am)

Asian share markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.6% while the Hang Seng is up 0.9%.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 19, 2019 10:33 AM

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS